Modeling of congenital amegakaryocytic thrombocytopenia using iPS cell technology

August 1, 2013
iPS cells generated from a CAMT patient reproduced the pathology of CAMT, in other words they were to some extent able to differentiate into white blood cells, but showed a marked loss of differentiation into both platelets and erythrocytes. It was established that the absence of thrombopoietin receptors also led to the failure of differentiation from multipotent hematopoietic progenitors to megakaryocyte-erythrocyte bipotent progenitors. Credit: Koji Eto, Center for iPS Cell Research and Application at Kyoto University

A research group led by researcher Shinji Hirata and Professor Koji Eto at CiRA has conducted a study in which iPS cells generated from a patient with congenital amegakaryocytic thrombocytopenia (CAMT) were induced to differentiate into blood cells in vitro and then used to undertake a detailed study of the differences between these and cells from healthy subjects. The researchers found that, in humans, thrombopoietin receptors are essential not only to the maintenance of the multipotent hematopoietic progenitor population and the production of platelets, but also to erythropoiesis (red blood cell production).

CAMT is caused by the congenital loss of thrombopoietin receptor-mediated intracellular signaling, resulting in a state of severe from birth and leading in the infant period to and gradual depletion first of red and then of white blood cells. This grave illness requires transplant for the patient to survive, but the lack of an adequate has hitherto been a hindrance to elucidating its pathology. In the present study, with the cooperation of one CAMT patient who has now received a and recovered, iPS cells (CAMT iPS cells) were generated and induced in vitro to differentiate into blood cells, whose behavior was analyzed in detail.

In the CAMT iPS cells, as in the CAMT patient's original blood cells, the thrombopoietin receptors were not functional. To check their ability to differentiate into megakaryocytes, platelets, erythrocytes (), and other cell types, these iPS cells were differentiated into multipotent hematopoietic progenitors, which can in turn differentiate into a range of different blood cell types. It was found that the multipotent hematopoietic progenitors derived from the CAMT iPS cells, unlike the iPS cells from healthy subjects, had impaired ability to develop not only into megakaryocytes and platelets, but also into erythrocytes. They did however retain some ability to differentiate into . These characteristics closely reflect the pathological state seen in CAMT patients (Fig. 1).

Next, the CAMT iPS cells were subjected to compensatory transduction of thrombopoietin via genetic engineering, which normalized the production of all three of megakaryocytes, , and erythrocytes. Altering the amount of thrombopoietin receptor introduced to bring it to the same level as in healthy subjects produced a differentiation pattern closely resembling that of healthy subjects, with a tendency to more erythrocytes than megakaryocytes. Intriguingly, overexpression promoted differentiation into megakaryocytes over differentiation into erythrocytes by CAMT patient-derived subjects. To investigate the fate-determining mechanism that decides between differentiation into megakaryocytes and erythrocytes, the researchers examined the transcription factors that operate downstream of thrombopoietin receptor signaling. This examination showed that, when thrombopoietin receptor signaling was intensified during the process of differentiation into megakaryocytes and erythrocytes, FLI1 was reduced in healthy subjects, but was in contrast elevated in CAMT iPS cells (Fig. 2).

Intensified thrombopoietin receptor signaling produced changes in FLI1 expression in iPS cells, resulting in enhanced differentiation into erythrocytes in cells from healthy subjects (left) and enhanced differentiation into megakaryocytes in cells from a CAMT patient (right). Credit: Koji Eto, Center for iPS Cell Research and Application at Kyoto University

By using iPS cells generated from CAMT patients, the research team succeeded in reproducing the pathological state of CAMT, in which the production of megakaryocytes and erythrocytes is markedly decreased compared to white blood cell production. Additionally, the team established that, in humans, thrombopoietin receptor signaling plays an important role in the maintenance of multipotent hematopoietic progenitors and their differentiation into megakaryocyte-erythrocyte progenitors, and is therefore essential to erythropoiesis. This is a finding which had not been possible with the mouse model that is in general use worldwide. In this way, using iPS cell technology has made it possible to not only analyze disease states, but also to investigate the mechanism of hematopoiesis. The findings of the study suggest that the thrombopoietin-like drugs used up till now to boost platelet count may also be useful in treating anemia. Going forward, iPS cells that model this disease will serve as an important tool in researching the origins of human hematopoiesis and the hematopoiesis pathway.

Explore further: Researchers identify novel approach to create red blood cells, platelets in vitro

Related Stories

Researchers identify novel approach to create red blood cells, platelets in vitro

May 30, 2013
A study led by Boston University School of Medicine has identified a novel approach to create an unlimited number of human red blood cells and platelets in vitro. In collaboration with Boston University School of Public Health ...

Surprise finding redraws 'map' of blood cell production

January 31, 2012
A study of the cells that respond to crises in the blood system has yielded a few surprises, redrawing the 'map' of how blood cells are made in the body.

Japanese team creates cancer-specific killer T cells from induced pluripotent stem cells

January 3, 2013
Researchers from the RIKEN Research Centre for Allergy and Immunology in Japan report today that they have succeeded for the first time in creating cancer-specific, immune system cells called killer T lymphocytes, from induced ...

Recommended for you

New understanding of how muscles work

August 23, 2017
Muscle malfunctions may be as simple as a slight strain after exercise or as serious as heart failure and muscular dystrophy. A new technique developed at McGill now makes it possible to look much more closely at how sarcomeres, ...

Scientists find RNA with special role in nerve healing process

August 22, 2017
Scientists may have identified a new opening to intervene in the process of healing peripheral nerve damage with the discovery that an "anti-sense" RNA (AS-RNA) is expressed when nerves are injured. Their experiments in mice ...

Mouse model of human immune system inadequate for stem cell studies

August 22, 2017
A type of mouse widely used to assess how the human immune system responds to transplanted stem cells does not reflect what is likely to occur in patients, according to a study by researchers at the Stanford University School ...

Researchers offer new targets for drugs against fatty liver disease and liver cancer

August 22, 2017
There may no silver bullet for treating liver cancer or fatty liver disease, but knowing the right targets will help scientists develop the most effective treatments. Researchers in Sweden have just identified a number of ...

Bio-inspired materials give boost to regenerative medicine

August 18, 2017
What if one day, we could teach our bodies to self-heal like a lizard's tail, and make severe injury or disease no more threatening than a paper cut?

Make way for hemoglobin

August 18, 2017
Every cell in the body, whether skin or muscle or brain, starts out as a generic cell that acquires its unique characteristics after undergoing a process of specialization. Nowhere is this process more dramatic than it is ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.